Lead Investigator Discusses Nivolumab Long-Term Survival Benefit in SCCHN

13:22 EDT 25 Apr 2018 | OncLive

Robert L. Ferris, MD, PhD, discusses the implications of the updated findings from the phase III CheckMate-141 trial in squamous cell carcinoma of the head and neck. 

More From BioPortfolio on "Lead Investigator Discusses Nivolumab Long-Term Survival Benefit in SCCHN"